MedTrace Logo

Imipenem and Sulbactam in the Treatment of Imipenem-resistant Acinetobacter Baumannii Bacteremia

NCT01374256 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2011-06-15

No results posted yet for this study

Summary

Infections caused by imipenem-resistant Acinetobacter baumannii are associated with high mortality and morbidity. The treatment choices for this resistant pathogen are limited.

The objective of the present proposal is to evaluate the effectiveness of combination therapy of imipenem and sulbactam in patients contracted with A. baumannii, and to correlate the clinical effect with the in vitro synergistic results.

Conditions

  • Acinetobacter Bacteraemia

Sponsors & Collaborators

Principal Investigators

  • Te-Li Chen, PhD · Taipei Veterans General Hospital, Taiwan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01374256 on ClinicalTrials.gov